Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Emory University | 224 |
| 2 | Moderna Inc | 95 |
| 3 | Gilead Sciences Inc | 92 |
| 4 | Arcus Biosciences Inc | 82 |
| 5 | Assembly Biosciences Inc | 64 |
| 6 | University of California | 63 |
| 7 | CSL Ltd | 59 |
| 8 | H Lundbeck AS | 51 |
| 9 | Arbutus Biopharma Corp | 46 |
| 10 | Personalis Inc | 43 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 3,107 |
| 2 | A61P | Therapeutic activity (drug indications) | 2,917 |
| 3 | C07K | Peptides | 977 |
| 4 | Y02A | Climate change adaptation | 884 |
| 5 | C12N | Microorganisms, enzymes | 757 |
| 6 | C07D | Heterocyclic compounds | 737 |
| 7 | G01N | Investigating / analysing materials | 409 |
| 8 | C07H | Sugars and derivatives | 291 |
| 9 | C12Q | Measuring/testing involving enzymes | 241 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 172 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Intravenous administration preparation of arbidol and salt thereof and preparation method | 2006 | 15 | |
| A kind of preparation method of arbidol HCl | 2016 | 13 | |
| Preparation method of arbidol hydrochloride | 2012 | 12 | |
| Preparation method and quality control method of arbidol hydrochloride tablet | 2011 | 12 | |
| Arbidol dry suspension and preparation method thereof | 2011 | 11 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 63 |
| 2021 | 39 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 9 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Stephen J. Polyak | University of Washington | 10 |
| 2 | Burtseva Ei | D.I. Ivanovsky Institute of Virology Russian Academy of Medical Sciences | 9 |
| 3 | Eve‐Isabelle Pécheur | Lyon 1 Université | 9 |
| 4 | Irina A. Leneva | Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences | 8 |
| 5 | Shuster Am | 5 |
| 6 | L'vov Dk | Sechenov University | 4 |
| 7 | Leneva Ia | Federal State University of Education | 4 |
| 8 | С. В. Борисевич | Ministry of Defence of the Russian Federation | 4 |
| 9 | Zifeng Yang | State Key Laboratory of Respiratory Disease | 4 |
| 10 | Shchelkanov MIu | Russian Academy of Sciences | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The cytokine storm of severe influenza and development of immunomodulatory therapy | 2015 | 743 | Influenza Virus Research Studies |
| Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment | 2020 | 579 | COVID-19 Clinical Research Studies |
| Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study | 2020 | 527 | COVID-19 Clinical Research Studies |
| Arbidol as a broad-spectrum antiviral: An update | 2014 | 501 | Influenza Virus Research Studies |
| Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 | 2020 | 437 | COVID-19 Clinical Research Studies |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Arbidol?
How has patent activity around Arbidol changed in recent years?
Which organizations are leading patent development for Arbidol?
What are the primary research topics associated with Arbidol?
Who are the most prolific authors publishing on Arbidol research?